EUVIMEDEUVIMED entdecken
Open Access

Mitochondrial metabolic reprogramming by a glutamine antagonist radioenhancer conjugate drives pyroptosis and antitumor immunity

Rundi Song iD, Jinhong Li, Chaoyu Wang iD, Langston Tillman iD, Yibin Mao, Yuxuan Xiong, Xuan Li, Ralph R Weichselbaum iD, Wenbin Lin iD

Science Advances · 30.10.2026 · 12 (44)

DOI: 10.1126/sciadv.aeh5903 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 30.10.2026. Verfasst von Rundi Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA. Hauptthemen laut MEDLINE: Mitochondria, Glutamine, Pyroptosis, Radiation-Sensitizing Agents. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Chicago, Westlake University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant glutamine metabolism undermines the efficacy of cancer radiotherapy (RT) by promoting DNA repair, increasing oxygen consumption, and imposing metabolic stress that compromises the viability and function of cytotoxic T lymphocytes (CTLs). Here, we report a mitochondria-enriched, metabolism-regulating monolayered metal-organic framework (MOF) nanoplatform, Hf-Ir/DON, constructed by incorporating the glutamine antagonist 6-diazo-5-oxo- l -norleucine (DON) into a radiosensitizing hafnium-iridium (Hf-Ir) MOF to inhibit glutaminolysis. This design markedly sensitizes tumor cells to RT and, upon x-ray irradiation, enables mitochondria-targeted RT-radiodynamic therapy with substantially enhanced reactive oxygen species accumulation. The resulting oxidative stress induces extensive DNA damage, mitochondrial dysfunction, and immunogenic tumor cell pyroptosis. Concurrently, Hf-Ir/DON alleviates metabolic constraints on activated T cells, preserving CTL viability while sustaining effector and memory functions. In a murine colon cancer model, low-dose RT combined with Hf-Ir/DON achieved >95% tumor growth inhibition. Further combination with anti–PD-L1 therapy induced regression of bilateral triple-negative breast tumors and prevented lung metastasis. These results establish a radiometabolic MOF nanoplatform that potentiates RT while promoting durable antitumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaGlutaminePyroptosisRadiation-Sensitizing AgentsAnimalsMiceMetabolic ReprogrammingHumansCell Line, TumorFemaleDiazooxonorleucineT-Lymphocytes, CytotoxicReactive Oxygen Species

Substanzen

GlutamineRadiation-Sensitizing AgentsDiazooxonorleucineReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Chemistry, University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA.
  • Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, University of Chicago, 5758 South Maryland Avenue, Chicago, IL 60637, USA.
  • Department of Chemistry, Westlake University, 600 Dunyu Road, Hangzhou 310030, Zhejiang, China.

ORCID-Profile: Rundi Song, Chaoyu Wang, Langston Tillman, Ralph R Weichselbaum, Wenbin Lin

Förderung

  • University of Chicago
  • Westlake University

Zitieren

APA

Song, R., Li, J., Wang, C., Tillman, L., Mao, Y., Xiong, Y., Li, X., Weichselbaum, R. R., & Lin, W. (2026). Mitochondrial metabolic reprogramming by a glutamine antagonist radioenhancer conjugate drives pyroptosis and antitumor immunity. Science Advances, 12(44). https://doi.org/10.1126/sciadv.aeh5903

Vancouver

Song R, Li J, Wang C, Tillman L, Mao Y, Xiong Y, et al. Mitochondrial metabolic reprogramming by a glutamine antagonist radioenhancer conjugate drives pyroptosis and antitumor immunity. Science Advances. 2026;12(44). doi:10.1126/sciadv.aeh5903

BibTeX
@article{Song2026,
  author = {Song, Rundi and Li, Jinhong and Wang, Chaoyu and Tillman, Langston and Mao, Yibin and Xiong, Yuxuan and Li, Xuan and Weichselbaum, Ralph R and Lin, Wenbin},
  title = {Mitochondrial metabolic reprogramming by a glutamine antagonist radioenhancer conjugate drives pyroptosis and antitumor immunity},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {44},
  doi = {10.1126/sciadv.aeh5903}
}
Kostenlos starten →